Pfizer Inc.’s request to expand use of its COVID-19 vaccine in adolescents will spur consideration by a US Centers for Disease Control and Prevention panel on how it should be administered relative to other inoculations on the adolescent immunization schedule.
On 9 April, Pfizer and partner BioNTech SE requested the US Food and Drug Administration amend the emergency use authorization for their mRNA
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?